Ruxolitinib was effective in patients with hematological malignancies who previously experienced steroid-dependent severe chronic graft versus host disease (cGVHD), according to a small study involving 19 individuals.
Participants had received unrelated donor (n=13) or matched sibling (n=6) transplant involving either blood (n=17) or marrow (n=2). After experiencing cGVHD, ruxolitinib was administered over a median of 18 months as a 2nd, 3rd, 4th, or 5th line salvage at 5 mg BID. Dosage was increased to 20 mg BID in 10 patients due to physician preference, patient weight, or cGVHD flare. Among the results:
- Complete resolution of clinical manifestations of cGVHD was observed in the skin (n=14), mouth (n=13), GI (n=8), liver (n=7), and lungs (n=1).
- Subjective improvement was reported in sclerodermatous, vaginal, ocular, and musculoskeletal cGVHD.
- Prednisone therapy was either discontinued (n=15) or reduced (n=4) after a median of 86 days of ruxolitinib treatment.
Khoury H, Kota K, Arellano M, et al. Ruxolitinib as sparing agent for steroid-dependent chronic graft-versus-host disease (cGVHD). Biol Blood Marrow Transplant. 2017; 23(3):S373. doi:10.1016/j.bbmt.2016.12.324.
This Week's Must Reads
Must Reads in Hematologic Malignancies
Long-term ibrutinib data in older patients, Barr PM et al. Haematologica. 2018;103(9):1502-10
Prognostic Score System for Patients with PMF, J Clin Oncol; ePub 2017 Dec 9; Gugliemelli, et al
These Patients Are More Apt to Be Depressed, Ann Hematol; ePub 2017 Dec 7; Shreders, et al
Survival Length Shortest in These Patients with MF, Eur J Haematol; ePub 2017 Dec 11; Masarova, et al
The Value of Ruxolitinib Before and After AlloSCT, Blood; ePub 2017 Dec 7; Poulose, Malysz, et al